Oral piritrexim, an effective treatment for metastatic urothelial cancer.

Abstract

Piritrexim is a lipid-soluble inhibitor of dihydrofolate reductase (DHFR) that enters tumour cells rapidly by passive diffusion, cannot be polyglutamated, and is as effective as methotrexate in inhibiting DHFR. Bioavailability after oral dosing is approximately 75%. We performed a phase II study with oral piritrexim in non-chemotherapy pretreated patients with metastatic urothelial cancer. Thirty-three patients were treated with 25 mg three times daily for 5 consecutive days, repeated weekly, with provision for dose escalation or reduction according to the toxicity observed. Of 29 evaluable patients, one patient achieved a complete response of 19+ weeks duration, and ten patients achieved a partial response with a median duration of 22 weeks (range 16-48), for a total response rate of 38%. Piritrexim was generally well tolerated, with myelosuppression as the major toxicity, that frequently required dose modification. We conclude that piritrexim appears to be an active agent in patients with metastatic urothelial cancer when administered as a 5-day, low-dose oral schedule. It would be attractive to investigate the combination of piritrexim and cisplatin.

• Authors: R de Wit, S B Kaye, J T Roberts, G Stoter, J Scott, J Verweij
• Journal: British journal of cancer (Br J Cancer) Vol. 67 Issue 2 Pg. 388-90 (Feb 1993) ISSN: 0007-0920 [Print] England
• PMID: 8431372 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Pyrimidines
• piritrexim
• Cisplatin
• Methotrexate

Topics

• Administration, Oral
• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy, secondary)
• Cisplatin (administration & dosage)
• Female
• Humans
• Male
• Methotrexate (administration & dosage)
• Middle Aged
• Pyrimidines (adverse effects, therapeutic use)
• Urologic Neoplasms (drug therapy, secondary)